Literature DB >> 11869903

BAFFled B cells survive and thrive: roles of BAFF in B-cell development.

Antonius G Rolink1, Fritz Melchers.   

Abstract

Interactions of BAFF (B-cell activating factor) with BAFF-R, one of three BAFF-binding receptors that are preferentially expressed on B cells, are essential for B-cell development, because defects in either the ligand or the receptor arrest progression from immature type-1 B cells to type-2 cells and mature cells; B1 B cells are unaffected. Transgenic BAFF overexpression leads to B-cell hyperplasia and autoimmune disease. In vitro, BAFF increases survival of immature and mature B cells; immature B cells also mature polyclonally to mature B cells, without proliferation. Upon BAFF-influenced differentiation, immature B cells change their surface-IgM signal transduction machinery and proliferate rather than undergoing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11869903     DOI: 10.1016/s0952-7915(02)00332-1

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  27 in total

1.  Insight into lymphoid development by gene expression profiling of avian B cells.

Authors:  Kimmo Koskela; Pekka Kohonen; Pia Nieminen; Jean-Marie Buerstedde; Olli Lassila
Journal:  Immunogenetics       Date:  2003-08-21       Impact factor: 2.846

2.  CD19+CD5+ B cells in primary IgA nephropathy.

Authors:  He Yuling; Xiao Ruijing; Ji Xiang; Jiang Yanping; Chen Lang; Li Li; Yang Dingping; Tan Xinti; Liu Jingyi; Tang Zhiqing; Bi Yongyi; Xia Bing; Wu Xinxing; Jin Youxin; David A Fox; Steven K Lundy; Ding Guohua; Tan Jinquan
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

3.  BOB.1/OBF.1 deficiency affects marginal-zone B-cell compartment.

Authors:  Tatjana Samardzic; Dragan Marinkovic; Peter J Nielsen; Lars Nitschke; Thomas Wirth
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice.

Authors:  Anshu Marathe; Suhasini Iyer; Zhihua Julia Qiu; Jennifer Visich; Donald E Mager
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

Review 5.  [Biologics therapy for systemic lupus erythematosus. Current situation].

Authors:  B F Hoyer; T Dörner
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

Review 6.  Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

Authors:  Stéphanie Haiat; Christian Billard; Claire Quiney; Florence Ajchenbaum-Cymbalista; Jean-Pierre Kolb
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

7.  Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen.

Authors:  Wei Li
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

8.  Factors supporting intrathecal humoral responses following viral encephalomyelitis.

Authors:  Timothy W Phares; Cristina P Marques; Stephen A Stohlman; David R Hinton; Cornelia C Bergmann
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

9.  DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF.

Authors:  Amanda L Gavin; Djemel Aït-Azzouzene; Carl F Ware; David Nemazee
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

10.  Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice.

Authors:  Daisuke Kawabata; Jeganathan Venkatesh; Meera Ramanujam; Anne Davidson; Christine M Grimaldi; Betty Diamond
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.